- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01760148
Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2) (sIFN-pred2)
Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Hepatitis C virus (HCV) infection rate in China is about 3%, which means about 30 million patients. Combination therapy of ribavirin and interferons (IFN) is the standard clinical treatment of HCV chronical infections. However, overall rate of sustained virological response (SVR) still do not exceed 60% even with ribavirin and peg-IFN. Due to several virus- and patient-related factors, treatment is even less successful in certain populations, especially in HCV genotype 1 infection. Thus the standard therapy duration is optimized according to the virus genotype in the clinical practice. Nowadays, two direct antiviral agents (DAAs) have been approved by Food and Drug Administration (FDA) of USA this year, which increases the SVR rate. However, high price, side effects and long duration render people to hesitate about the addition of the third drug in the traditional prescription.
Predicting the outcome of traditional therapy is the cornerstone of the personalized therapy for HCV infected patients. In order to obtain an accurate prediction, different methods have been tried. Several indicators have been suggested to predict the final treatment outcomes. Rapid Virus Response (RVR), which indicates the non-detectable virus at the forth week since therapy starts, has been used to predict the final treatment outcome.Other indicators, including virus genotype, host genotype of IL-28B, human race and interferon stimulated genes (ISG) expression have also been shown to relate to and be able to predict the treatment outcomes to some extent. Here the investigators propose that the HCV virus dynamics analysis will give a more precise prediction for the therapy outcome.
The general idea is that blood HCV titration data is obtained continuously in the early treatment period (first 2 weeks) of the patients who have strictly followed the therapy method. These titration data will be used to draw virus dynamics curve and calculate the corresponding parameters individually. The parameter(s) that can distinguish patients who reach the therapy evaluation standard from those who failed to reach the evaluation standard will be selected out, and such parameter(s) may be used to predict the therapy outcome of a new patient in the early stage of his/her treatment.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Chen Yang, PhD
- Telefonnummer: +8615221296266
- E-Mail: yangch@zoho.com
Studieren Sie die Kontaktsicherung
- Name: Xiumei Chi, PhD
- Telefonnummer: +862154921375
- E-Mail: xiumeichi@hotmail.com
Studienorte
-
-
Jilin
-
Changchun, Jilin, China, 130061
- Rekrutierung
- First Hospital Jilin University
-
Kontakt:
- Yu Pan, PhD/MD
- Telefonnummer: 0431-88782120
- E-Mail: panyu20000@yahoo.com.cn
-
Kontakt:
- Xiumei Chi, PhD/MD
- Telefonnummer: 0431-88782222
- E-Mail: xiumeichi@hotmail.com
-
Hauptermittler:
- Yu Pan, PhD/MD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test
- Serum HCV-RNA > 3 log IU/ml
- Has been infected by HCV for more than 6 months
- ALT,AST have been elevated continuously, inflammation and necrosis have been observed according to the histology diagnosis (G>=2),modest liver fibrosis (S>=2)For those patients whose ALT are normal,treatment accord to the liver biopsy. If obvious fibrosis has been detected (S2,S3),treatment should be done.For those S0,S1 stage patients, treatment could be delayed, but ALT/AST should be assayed every 3-6 months.
- Compensated liver disease
- Patients have never been treated with traditional interferon plus ribavirin or peginterferon plus ribavirin
Exclusion Criteria:
-
History:
- Has history of decompensated liver diseases
- Has been treated with other anti-virus drugs,or anti-tumor drugs,immuno-suppression drugs
- Has a history of autoimmune hepatitis
- History of a severe seizure disorder or current anticonvulsant use
- History or other evidence of a medical condition associated with chronic liver disease other than HCV which would make the patient, in the opinion of the investigator, unsuitable for the study (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures)
- Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4g/dL (as may be seen with ribavirin therapy) would not be well-tolerated
- History of thyroid disease poorly controlled on prescribed medications, elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease
Current condition:
- Pregnant women or women during the lactation period
- Co-infected with hepatitis b virus or human immunodeficiency virus
- Liver cancer or alpha-fetoprotein > 100ng/ml
- Blood neutrophils count < 1500/mm3, or platelets count < 90000/mm3
- Female hemoglobin <11.5g/dL, male hemoglobin <12.5g/dL
- Blood creatinine > 1.5 ULN
- Have severe mental diseases,especially depression
- Severe pulmonary dysfunction
- Severe cardiovascular disease
- Uncontrolled diabetes
- Uncontrolled thalassemia
- Evidence of alcohol abuse (alcohol consumption>40 g/day)
- Unwillingness to provide informed consent or abide by the requirements of the study
- Local or System malignancy unstable status
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Interferon und Ribavirin
Alle Patienten folgten dem Standardbehandlungsprotokoll.
|
Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection. Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Absolute Blood HCV RNA Copies at designed time points
Zeitfenster: 0hr,24hr,1wk,2wk,4wk,6wk,12wk,24wk,48wk,72wk
|
Blood HCV RNA copies were assayed with Roche - COBAS® AmpliPrep/COBAS® TaqMan® HCV Test.
|
0hr,24hr,1wk,2wk,4wk,6wk,12wk,24wk,48wk,72wk
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
HCV-Genotyp
Zeitfenster: Grundlinie
|
HCV NS5A wird in einen T-Vektor kloniert und für die Evolutionsanalyse sequenziert.
|
Grundlinie
|
Geschichte des Drogenmissbrauchs
Zeitfenster: Grundlinie
|
Die Patienten werden zu ihrer Vorgeschichte des Drogenkonsums befragt.
|
Grundlinie
|
IL-28B-Polymorphismus
Zeitfenster: Grundlinie
|
IL28-Genpolymorphismus, rs8099917, rs12979860 usw
|
Grundlinie
|
Alanine Aminotransferase (ALT) and Aspartate transaminase (AST)
Zeitfenster: Baseline,4wk,12wk,24wk,48wk
|
ALT AST are assayed to detect the hepatic function.
|
Baseline,4wk,12wk,24wk,48wk
|
Fibrosis stage
Zeitfenster: Baseline,4wk,12wk,24wk,48wk
|
Fibrosis is analyzed with Fibroscan.
|
Baseline,4wk,12wk,24wk,48wk
|
Regular blood test
Zeitfenster: Baseline,4wk,12wk,24wk,48wk
|
The distribution and absolute count of the different types of blood cells are assayed.
|
Baseline,4wk,12wk,24wk,48wk
|
Electrocardiography
Zeitfenster: Baseline,4wk,12wk,24wk,48wk
|
Electrocardiography is taken to avoid severe side effects.
|
Baseline,4wk,12wk,24wk,48wk
|
Alcohol ,smoking condition
Zeitfenster: Baseline,4wk,12wk,24wk,48wk
|
Patients are asked whether they take alcohol or smoke cigarettes during the therapy period.
|
Baseline,4wk,12wk,24wk,48wk
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienstuhl: Bing Sun, Doctor, Chinese Academy of Sciences
- Studienleiter: Chen Yang, Doctor, Chinese Academy of Sciences
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001 Sep 22;358(9286):958-65. doi: 10.1016/s0140-6736(01)06102-5.
- Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998 Oct 2;282(5386):103-7. doi: 10.1126/science.282.5386.103.
- Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007 Jul;46(1):16-21. doi: 10.1002/hep.21657.
- Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N. A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther. 2010 Jun;87(6):706-13. doi: 10.1038/clpt.2010.35. Epub 2010 May 12.
- Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004 Dec 16;432(7019):922-4. doi: 10.1038/nature03153.
- Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, Papassotiropoulos A, Roth V, Heim MH. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011 Mar;140(3):1021-31. doi: 10.1053/j.gastro.2010.11.039. Epub 2010 Nov 25.
- Araujo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES, Layden TJ, Cotler SJ, Barone AA. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat. 2011 Apr;18(4):e52-60. doi: 10.1111/j.1365-2893.2010.01358.x.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Leberkrankheiten
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, chronisch
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Antimetaboliten
- Antineoplastische Mittel
- Immunologische Faktoren
- Interferone
- Interferon-alpha
- Ribavirin
- Interferon alpha-2
Andere Studien-ID-Nummern
- 2012ZX10002007
- 2009ZX10004-105-jida02 (Andere Zuschuss-/Finanzierungsnummer: Ministry of Science and Technology)
- 2008ZX10002-014-jida02 (Andere Zuschuss-/Finanzierungsnummer: Ministry of Science and Technology)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur interferon alpha 2b
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendiertNeoplasma hämatopoetischer und lymphoider Zellen | Bösartiges solides Neoplasma | Symptomatische COVID-19-Infektion LaborbestätigtVereinigte Staaten
-
Emory UniversityCURE Childhood Cancer, Inc.AbgeschlossenJuvenile pilozytische Astrozytome | SehbahngliomeVereinigte Staaten
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, nicht rekrutierendPrimäre Myelofibrose | Sekundäre MyelofibroseVereinigte Staaten
-
Institute of Hematology & Blood Diseases Hospital...RekrutierungEssentielle ThrombozytopenieChina
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupZurückgezogen
-
The Wistar InstituteUniversity of Pennsylvania; Merck Sharp & Dohme LLCAbgeschlossenHIV-1-InfektionVereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossen
-
Qianfoshan HospitalNoch keine Rekrutierung
-
Emory UniversityBayerAbgeschlossen
-
Institute of Hematology & Blood Diseases Hospital...RekrutierungEssentielle ThrombozytopenieChina